Long-lasting control with eribulin in a taxane pretreated metastatic breast cancer patient

被引：3

作者：

Iorfida, Monica ^{[1
]}

Mazza, Manuelita ^{[1
]}

机构：

[1] European Inst Oncol, Div Med Senol, Milan, Italy

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 15期

关键词：

breast cancer; eribulin; response; HALICHONDRIN B ANALOG; PHASE-II; MESYLATE; E7389; ANTHRACYCLINE;

D O I：

10.2217/fon.15.149

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Effective treatment options for patients with metastatic breast cancer resistant to anthracyclines and taxanes are limited. Moreover, many chemotherapeutic agents need to be interrupted due to toxicity. Here we report an extremely long duration of chemotherapy with eribulin (11 courses) in a taxane-pretreated metastatic breast cancer patient. Therapy was well tolerated with no worsening of pre-existing neuropathy, achieving excellent outcomes and a good quality of life. This report adds to the pool of knowledge regarding the use of this important new metastatic breast cancer chemotherapeutic agent.

引用

页码：23 / 26

页数：4

共 20 条

[1]

Abraxis Bioscience Inc, 2007, ABRAXANE INJ SUSP PA

[2]

[Anonymous], 2012, HAL ER MES INJ PRESC

[3]

[Anonymous], 2007, TAX PACL PRESCR INF

[4] Second consensus on medical treatment of metastatic breast cancer [J].

Beslija, S. ;

Bonneterre, J. ;

Burstein, H. ;

Cocquyt, V. ;

Gnant, M. ;

Goodwin, P. ;

Heinemann, V. ;

Jassem, J. ;

Koestler, W. J. ;

Krainer, M. ;

Menard, S. ;

Petit, T. ;

Petruzelka, L. ;

Possinger, K. ;

Schmid, P. ;

Stadtmauer, E. ;

Stockler, M. ;

Van Belle, S. ;

Vogel, C. ;

Wilcken, N. ;

Wiltschke, C. ;

Zielinski, C. C. ;

Zwierzina, H. .

ANNALS OF ONCOLOGY, 2007, 18 (02) :215-225

[5]

Bristol-Myers Squibb Company, 2007, IX KIT IX PRESCR INF

[6] Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].

Cortes, Javier ;

O'Shaughnessy, Joyce ;

Loesch, David ;

Blum, Joanne L. ;

Vahdat, Linda T. ;

Petrakova, Katarina ;

Chollet, Philippe ;

Manikas, Alexey ;

Dieras, Veronique ;

Delozier, Thierry ;

Vladimirov, Vladimir ;

Cardoso, Fatima ;

Koh, Han ;

Bougnoux, Philippe ;

Dutcus, Corina E. ;

Seegobin, Seth ;

Mir, Denis ;

Meneses, Nicole ;

Wanders, Jantien ;

Twelves, Chris .

LANCET, 2011, 377 (9769) :914-923

[7] Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine [J].

Cortes, Javier ;

Vahdat, Linda ;

Blum, Joanne L. ;

Twelves, Chris ;

Campone, Mario ;

Roche, Henri ;

Bachelot, Thomas ;

Awada, Ahmad ;

Paridaens, Robert ;

Goncalves, Anthony ;

Shuster, Dale E. ;

Wanders, Jantien ;

Fang, Fang ;

Gurnani, Renuka ;

Richmond, Elaine ;

Cole, Patricia E. ;

Ashworth, Simon ;

Allison, Mary Ann .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (25) :3922-3928

[8] Metastatic breast cancer: why are we here and where are we going? [J].

Crown, John .

EJC SUPPLEMENTS, 2006, 4 (13) :2-5

[9] The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth [J].

Jordan, MA ;

Kamath, K ;

Manna, T ;

Okouneva, T ;

Miller, HP ;

Davis, C ;

Littlefield, BA ;

Wilson, L .

MOLECULAR CANCER THERAPEUTICS, 2005, 4 (07) :1086-1095

[10]

Kaufman PA, 2012, 2012 SAN ANT BREAST

← 1 2 →